TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adenosine-induced Stress Dynamic Myocardial Perfusion Imaging With Dual-source CT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women patients, with age ranging 40-80.~2. Suspected coronary artery disease who are supposed to undergo invasive coronary angiography with appropriate clinical indications~3. Patients who are willing to sign the informed consent form~Exclusion Criteria:~1. Contraindication of CT Known allergy to iodinated contrast media or history of contrast-induced nephropathy Decreased renal function: elevated serum creatinine(\>1.5mg/dl) Contraindication to beta-blockers Severe arrhythmia: arterial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block)~2. Contraindication of MRI Claustrophobia Metallic hazards Pacemaker implant eGFR\<30 ml/min~3. Unstable or uncooperative patients~4. Limited life expectancy due to cancer or end-stage renal or liver disease~5. Evidence of severe symptomatic heart failure (NYHA Class III or IV)~6. Previous myocardial infarction, coronary artery intervention, coronary artery bypass surgery, or other cardiac surgery

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CT perfusion group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy children with a diagnosis of dysphonia age 3-18 years.~2. Dysphonia must be present for at least one month duration.~3. May have vocal cord nodules present.~4. Pre-enrollment flexible fiberoptic laryngoscopy must not show any potentially life-threatening cause, including but not limited to laryngeal papillomatosis, congenital glottic webs, vocal cord paralysis, or benign and malignant neoplasms.~5. Must be able to cooperate with recording of voice for analysis(3 seconds of sustained vowel).~6. Caregiver must be able to read, write, and understand English.~7. Patient with history of diagnosed asthma must have their asthma well controlled and treated at the time of enrollment for study.~Exclusion Criteria:~1. Dysphonia must not be due to a potentially life-threatening cause, such as laryngeal papillomatosis, congenital glottic webs, vocal cord paralysis, or benign and malignant neoplasms. This will be determined by visualization with flexible fiberoptic laryngoscopy.~2. Dysphonia must not be due to an acute upper respiratory infection.~3. Must not have been treated with proton pump inhibitor medication in the past 12 months.~4. Inability of child to cooperate with recording of voice for analysis.~5. Inability of caregiver to read, write, and understand English.~6. Mental retardation, cognitive impairment, or developmental delay.~7. History of allergic reaction of any kind to lansoprazole or any other proton pump inhibitor.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Lansoprazole and dietary control (Type: ACTIVE_COMPARATOR): Lansoprazole and dietary control
- Placebo and dietary control (Type: PLACEBO_COMPARATOR): Dietary control and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with a diagnosis of RRMS according to the McDonald criteria (2005)~* At least 18 years of age~* Patients are treated with IFN-beta for RRMS. The decision to treat with IFN beta will be independent from this study protocol.~* Patients will be either newly diagnosed, who are going to start IFN beta therapy for the first time or RRMS patients who suffer from FLS while being treated with IFN beta.~* Insufficient blood levels of 25-hydroxy-vitamin D (below 75nmol/l according to current definitions.~* EDSS score up to 7~* Willing and able to give informed consent~Exclusion Criteria:~* Patients having abnormalities of vitamin D related hormonal system other than low dietary intake or decreased sun exposure will be excluded. Namely, malabsorption \[Celiac, Whipple, Inflammatory bowl disease, Intestinal bypass surgery, Short bowel syndrome, Cirrhosis, Nephrotic syndrome, Hyperthyroidism, Renal failure \[creatinine clearance of less than 40 ml/min\], Rickets, Hypoparathyroidism, Hypercalcemia at baseline, known malignancy, granulomatous disorders (Sarcoidosis, Tuberculosis, Silicosis) and Lymphomas.~* Patients who take medications that influence vitamin D metabolism, other than corticosteroids, will be also excluded. Namely, Orlistat, Anticonvulsants \[Phenobarbital, Primidone, Phenytoin\], Rifampin, Isoniazide, ketoconazole, 5FU and Leucovorin~* Patients with conditions with increased susceptibility to hypercalcemia will be excluded too: known arrhythmia or heart disease, treatment with Digitalis, or Hydrochlorothiazide.and those who suffer from nephrolithiasis.~* Other Central Nervous System disorders than RRMS~* Psychiatric disorders such as psychosis, bipolar disorder or substance abuse~* Pregnancy~* Contra-indication to treatment with IFN-beta

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High dose vitamin D (Type: EXPERIMENTAL): 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
- Low dose vitamin D (Type: ACTIVE_COMPARATOR): 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* an incomplete C6 ASIA C (Central Cord) spinal cord injury~* lower motor function impaired and suffers from significant spasticity (Ashworth scale 4)~* able to ambulate approximately 10-20 feet with a rolling walker and minimal assistance~* has sufficient endurance to complete at least two 20-minute therapy sessions per day~* cognitive abilities are intact~Exclusion Criteria:~* psychiatric diagnosis~* medical contraindications~* history of bleeding disorders~* allergy to anesthesia~* acute or progressive disease~* active implantable device

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Intramuscular Electrical Stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TissueLink Versus SEAMGUARD After Distal Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age equal or above 18 years~2. Accepted for elective distal pancreatectomy for any indication~Exclusion from randomization process:~* Thickness of pancreas on preoperative CT scan images \> 2.5 cm at the site of expected transection in anterior-posterior diameter. This will be reviewed by the surgeon the day before the surgeon sees the patient to predetermine the appropriateness of the patient for the study.~General study exclusion criteria:~1. Current immunosuppressive therapy~2. Chemotherapy within 2 weeks before operation~3. Bevacizumab (Avastin™) treatment not completed at least 6 weeks before operation~4. Radiotherapy before operation~5. Inability to follow the instructions given by the investigator~6. Lack of compliance~7. Persons unable or unwilling to give informed consent to participate in this study~8. Pregnant women~9. Prisoners~10. Institutionalized individuals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SEAMGUARD with bioabsorbable staple (Type: ACTIVE_COMPARATOR): In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
- TissueLink with radiofrequency ablation (Type: ACTIVE_COMPARATOR): After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A(f)MAZE-CABG Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Legal age in host country~* Scheduled for CABG surgery~* Patient suffering from persistent or long-standing persistent AF~* Patients having the ability to fully comply with the study requirements~* Life expectancy \> 2 years~* Patients who have given written informed consent to participate in the study~Exclusion Criteria:~* Clinically significant local or systemic infection or active endocarditis~* Sutures, pacing/defibrillator leads on the left side of the heart, valve prostheses or rings, or other implanted material in or adjacent to target treatment area.~* Stent in the coronary artery preventing an adequate mitral line~* Any other concomitant operation on the heart~* Previous heart surgery~* Patients who are or may potentially be pregnant~* Previous catheter ablation for atrial arrhythmia~* LA size more than 60 mm in apical view on Trans-Thoracic Echocardiogram (TTE)~* LA thrombus on intra-operative Trans-Oesophageal Echocardiogram (TOE)~* Known contraindication to Amiodarone~* Inability to undergo TOE~* Patients who are unable to give full informed consent for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Concomitant HIFU ablation (Type: ACTIVE_COMPARATOR): HIFU AF Ablation
- Best medical treatment (Type: NO_INTERVENTION): Best medical treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Galantamine in Tic Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM IV criteria for the diagnosis of Tourette's syndrome, chronic motor or chronic vocal tic disorder~* Accepted method of birth control~Exclusion Criteria:~* Preganancy or nursing~* Unstable medical illness~* Unstable psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of metastatic or locally advanced non-hematological cancer~* Patients with solid tumors refractory to therapy or for whom no therapy exists~Exclusion Criteria:~* Five or more prior chemotherapy lines for metastatic disease~* Eastern Cooperative Oncology Group (ECOG) performance status \>2~* Patients having discontinued previous specific anti-cancer treatment~* Patients who have not recovered from all toxic effects from previous specific anti-cancer treatment (excluding alopecia)~* Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment~* No adequate birth control methods~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): 1 hour IV infusion D1
- Arm B (Type: EXPERIMENTAL): 1 hour IV infusion D1, D8, D15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women \>18 years~* Liver cirrhosis confirmed by fibroscan (\>20 kPa), or by imaging with signs of an irregular liver surface with collaterals, or clinically by cirrhosis stigmata~* Refractory ascites Definition: failure to respond to or intolerance to high dose diuretics (spironolactone up to 400mg/day and furosemide up to 160mg/day) and early ascites recurrence (reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization or ≥2 paracentesis within last 3 months)~* Urine sodium excretion \<60 mmol/24 hour~* Serum creatinine \<150 µmol/L~* Child-Turcotte-Pugh score of B or C (\<13)~* Bilirubin \<150 µmol/L~* Prothrombin time (PP) 0.20-0.60 (INR 1.3-2.5)~* Systolic blood pressure ≥95 mmHg~* Written informed consent to participate in the clinical trial~Exclusion Criteria:~* Gastrointestinal bleeding within 2 weeks prior to inclusion~* Proteinuria \>500 mg/day~* Hemoglobin \<5.5 mmol/L~* Spontaneous bacterial peritonitis within 2 weeks prior to inclusion~* Loculated ascites~* Hepatic encephalopathy grade 2-4 (West-Haven classification)~* Obstructive uropathy~* Primary kidney disease~* Known diagnosis of congestive heart failure~* Known diagnosis of acute-on-chronic liver failure~* Known diagnosis of systemic inflammatory response syndrome~* Acute infections by known diagnosis and/or antibiotic treatment~* Known HIV infection~* Known allergy to the investigational drug or other natriuretic peptides~* Treatment with dobutamine, levosimendan, milrinone, any phosphodiesterase inhibitor, octreotide, midodrine, vasopressin, dopamine or other vasopressors within 2 weeks prior to inclusion~* Nephrotoxic drugs within 1 month prior to inclusion~* Fertile women not using contraception, either an intrauterine device or hormonal contraception~* Positive pregnancy test in pre-menopausal women or in breast-feeding women~* Participation in an interventional clinical drug trial within 1 month prior to inclusion~* Legal incapacity or limited legal capacity~* Patients who are employees or relatives of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ularitide (Type: EXPERIMENTAL): Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo. Continuous IV infusion for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer~2. Age ≥ 18 years~3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception: 2 methods of birth control, prior to study entry ad for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.~4. Ability to understand a written informed consent document, and the willingness to sign it~5. At least 4 weeks post-completion of chemotherapy~6. Adequate organ function within 14 days start of study start:~   1. Absolute neutrophil count (ANC) ≥ 1.5 X 10\^9/L~  2. Hemoglobin (Hgb) ≥9g/dL~  3. Platelets (plt) ≥ 100 x 10\^9/L~  4. Potassium within normal range, or correctable with supplements;~  5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is present;~  6. Serum total bilirubin ≤ 1.5 x ULN~  7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min~Exclusion Criteria:~1. Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~2. Currently on a leukotriene inhibitor or used within the past 6 months~3. Prior chest wall radiation~4. Pregnant or breastfeeding~5. Hepatic impairment as defined by:~   • AST(SGOT) \> 2.5X institutional ULN and ALT(SGPT) \> 2.5X institutional ULN~6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Zafirlukast (Type: EXPERIMENTAL): Zafirlukast
- Standard of Care (no intervention) (Type: OTHER): Standard of Care (no intervention)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients above the age of 2 months and post-gestational age to 44 weeks and less than or equal to 2 years with signs and symptoms of bronchiolitis~* clinical respiratory score (CRS) of less than or equal to 4~* principle diagnosis of bronchiolitis (International Classification of Diseases-9: 466, 466.11 and 466.19)~* Patient admitted to the Pediatric Hospitalist Medicine (PHM) group~* Patient with associated hypoxemia and/or respiratory distress requiring low flow O2 nasal cannula (NC) management (2L/min or less)~Exclusion Criteria:~* age less than 2 months~* age less than post-gestational age 44 weeks~* CRS greater than 4~* associated hypoxia~* already using NoseFrida at home~* chronic lung disease~* oro-facial abnormalities~* cardiac abnormalities

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- NoseFrida (Type: EXPERIMENTAL): If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
- NeoSucker (Type: NO_INTERVENTION): The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protocols for Improved in Vitro Fertilization (IVF) Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infertile patients~* Undergoing IVF~* Antral Follicle Count Less than 10~* Prior history of less than 5 oocytes generated during an IVF cycle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues